RecruitingNCT07375225
Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy
Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy - The ALINET Registry
Sponsor
Federico II University
Enrollment
1,500 participants
Start Date
Dec 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria1
- \- Patients under alirocumab 300mg treatment.
Exclusion Criteria2
- Age \< 18 years o \> 80 years;
- Patients who refuse to participate and to sign informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPraluent (Alirocumab)
Alirocumab 300 mg injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07375225
Related Trials
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
NCT0749117218 locations
An Efficacy and Safety Study of Akkermansia Muciniphila AKM Lab-01 in Hypercholesterolaemia
NCT069742661 location
LATAM LOWERS LDL-C
NCT0650144311 locations
efficacy of LOw dose antihypertensive and lipid lowering pill combinations To improve stroke oUtcomeS (LOTUS)
ACTRN1262400127951614 locations
Effect of Fucoidan on glucose control and markers of cardiometabolic health after chronic dosing
ACTRN126140004956281 location